STAT3 is an important regulator in cancer; substantial evidence suggests that STAT3 is constitutively activated in many cancers, significantly contributing to tumor development and metastasis, and is associated with cancer severity and unfavorable prognosis.[42] Given that piR‐RCC inhibits RCC progression by down‐regulating STAT3 expression, we investigated whether the combination of piR‐RCC overexpression and stattic (a STAT3 inhibitor) would synergistically inhibit RCC progression. The gene discussed is STAT3; the disease is renal cell carcinoma.